Your browser doesn't support javascript.
loading
Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy.
Wu, Ruo; Song, Yafeng; Wu, Shiwen; Chen, Yongchang.
Afiliação
  • Wu R; State Key Laboratory of Primate Biomedical Research & Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming 650500, China.
  • Song Y; Yunnan Key Laboratory of Primate Biomedical Research, Kunming 650500, China.
  • Wu S; Institute of Sport and Health Science, Beijing Sport University, No.48 Xinxi Road, Haidian District, Beijing 100084, China.
  • Chen Y; Department of Neurology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China.
Fundam Res ; 2(6): 885-893, 2022 Nov.
Article em En | MEDLINE | ID: mdl-38933385
ABSTRACT
Duchenne muscular dystrophy (DMD) is a serious genetic neuromuscular rare disease that is prevalent and caused by the mutation/deletion of the X-linked DMD gene that encodes dystrophin. Utrophin is a dystrophin homologous protein on human chromosome 6. Dystrophin and utrophin are highly homologous. They can recruit many dystrophin-glycoprotein complex (DGC)-related proteins and co-localize at the sarcolemma in the early stage of human embryonic development. Moreover, utrophin is overexpressed naturally at the mature myofiber sarcolemma in DMD patients. Therefore, utrophin is considered the most promising homologous protein to replace dystrophin. This review summarizes various modulating drugs and gene therapy approaches for utrophin replacement. As a universal method to treat DMD disease, utrophin has a promising therapeutic prospect and deserves further investigation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Fundam Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Fundam Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China